Haha it's a good question and I'm not sure exactly. Without having more specific information, I can't really comment with any authority and as such, this is merely just for discussion.
The City of Hope demonstrated that bisantrene was effective at sensitizing AML cells to other therapies, so I just assume future programs will include things like this where possible.
I've based my assumptions off what I know - an FTO inhibitor works better in combination, FTO causes resistance to radiotherapy, and radiotherapy is worth bank $$. When I saw the term safety used, it threw me a bit and made me lean towards radiotherapy as a synergy partner.
Radiotherapy can be used in many ways for lung cancer like before and after surgery, during and with chemo, after surgery, metastasis, and as a primary treatment. I'm finding conflicting data but drugs commonly used could be alkylating agents, TKI treatments, or something else. They all come with their inherent risks or side effects.
And so, I'm assuming 'safety' refers to a first-line treatment for patients who are receiving radiation therapy who also overexpress FTO. I don't think I have found a study yet that has shown an association between lung cancer prognosis and high concentrations of m6A (either low FTO or high writers [METTL3/METTL14]), which is encouraging.
- Forums
- ASX - By Stock
- RAC
- Ann: Race investor briefing & updated presentation
Ann: Race investor briefing & updated presentation, page-19
-
- There are more pages in this discussion • 316 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.95 |
Change
0.005(0.26%) |
Mkt cap ! $331.3M |
Open | High | Low | Value | Volume |
$1.93 | $1.96 | $1.91 | $91.41K | 47.18K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 335 | $1.93 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.95 | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 335 | 1.930 |
1 | 900 | 1.925 |
3 | 1927 | 1.920 |
1 | 900 | 1.915 |
3 | 13966 | 1.910 |
Price($) | Vol. | No. |
---|---|---|
1.945 | 1000 | 1 |
1.950 | 2664 | 2 |
1.970 | 7194 | 1 |
1.975 | 2000 | 1 |
1.980 | 18338 | 1 |
Last trade - 10.19am 16/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online